N-Trifluoracetyl-R-prolylchlorid | 71890-93-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-Trifluoracetyl-R-prolylchlorid
• 英文别名: N-trifluoroacetyl-D-prolyl chloride；1-(2,2,2-trifluoroacetyl)pyrrolidine-2-carbonyl chloride；(S)-1-(2,2,2-trifluoroacetyl)pyrrolidine-2-carbonyl chloride；(2R)-1-(2,2,2-trifluoroacetyl)pyrrolidine-2-carbonyl chloride
• CAS: 71890-93-2
• 化学式: C₇H₇ClF₃NO₂
• 分子量: 229.586
• InChiKey: NUOYJPPISCCYDH-SCSAIBSYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  37.4
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  tert-butyl 5-(2-(3-aminophenyl)quinazolin-4-ylamino)-1H-indazole-1-carboxylate 、 N-Trifluoracetyl-R-prolylchlorid 在 4-二甲氨基吡啶 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 18.0h， 以46%的产率得到tert-butyl 5-(2-(3-((R)-1-(2,2,2-trifluoroacetyl)pyrrolidine-2-carboxamido)phenyl)quinazolin-4-ylamino)-1H-indazole-1-carboxylate
  参考文献：
  名称：

  WO2006/105081

  摘要：

  公开号：

文献信息

• PROCESS FOR PRODUCING INDOLINE COMPOUNDS AND INTERMEDIATES FOR THE PRODUCTION OF THE SAME
  申请人：TOKYO TANABE COMPANY LIMITED

  公开号：EP0810214A1

  公开（公告）日：1997-12-03

  This invention concerns a method for the production of a 3-arylindoline compound represented by the general formula (wherein R1 represents an optionally substituted phenyl group or an aromatic heterocyclic group and R2 represents a hydrogen atom, a halogen atom, a lower alkyl group, a hydroxy group, a lower alkoxy group, a carbamoyl group, or a lower alkoxycarbonyl group) which is used for the production of a 1-acyl-3-arylindoline compound represented by the general formula (wherein R1 and R2 have the same meanings as defined above and R3 represents the following group) which is the 5-HT3 receptor antagonist, based on the fact that a 1-acyl-3-arylindole compound obtained by having a removable electron withdrawing group linked thereto by acylating the 1 position of a 3-arylindole compound with such an organic acid as carboxylic acid or sulfonic acid easily undergoes a catalytic reduction under neutral or acidic conditions and gives rise to a 1-acyl-3-arylindoline compound and that an optically active 1-acyl-3-arylindole compound obtained by the acylation with an organic acid such as optically active carboxylic acid or sulfonic acid produces an optically active 1-acyl-3-arylindoline compound with high selectivity by the reaction of a catalytic reduction.

  本发明涉及一种生产通式如下的 3-芳基吲哚啉化合物的方法 (其中 R1 代表任选取代的苯基或芳香杂环基团，R2 代表氢原子、卤素原子、低级烷基、羟基、低级烷氧基、氨基甲酰基或低级烷氧羰基）的方法，该方法用于生产由通式表示的 1-酰基-3-芳基吲哚啉化合物。 (其中 R1 和 R2 的含义与上述定义相同，R3 代表下列基团） 是 5-HT3 受体拮抗剂、通过用羧酸或磺酸等有机酸对 3-芳基吲哚化合物的 1 位进行酰化而得到的 1-酰基-3-芳基吲哚化合物，在中性或酸性条件下很容易发生催化还原反应，生成 1-酰基-3-芳基吲哚化合物。3-芳基吲哚化合物，而通过与有机酸（如具有光学活性的羧酸或磺酸）酰化得到的具有光学活性的 1-酰基-3-芳基吲哚化合物通过催化还原反应以高选择性生成具有光学活性的 1-酰基-3-芳基吲哚化合物。
• Materials for separating and detecting enantiomers of amphetamine or methamphetamine, and their application
  申请人：——

  公开号：US20020187562A1

  公开（公告）日：2002-12-12

  The present invention discloses a material for chromatography comprising an antibody capable of differentiating at least an enantiomer of amphetamine or methamphetamine, and a support, wherein the antibody is bonded to the support. The material is capable of being employed to differentiate at least an enantiomer of amphetamine or methamphetamine in a sample. Also disclosed in the present invention are the methods and kits for detecting or identifying at least an enantiomer of amphetamine or methamphetamine in a sample, and methods for separating or purifying at least an enantiomer of amphetamine or methamphetamine from a sample.

  本发明公开了一种色谱材料，该材料包括一种能够区分苯丙胺或甲基苯丙胺的至少一种对映体的抗体和一种支持物，其中抗体与支持物结合。该材料可用于区分样品中的苯丙胺或甲基苯丙胺的至少一种对映体。本发明还公开了检测或鉴定样品中至少一种苯丙胺或甲基苯丙胺对映体的方法和试剂盒，以及从样品中分离或纯化至少一种苯丙胺或甲基苯丙胺对映体的方法。
• EP0677041A4
  申请人：——

  公开号：EP0677041A4

  公开（公告）日：1995-08-29
• CHEMICAL COMPOUNDS
  申请人：SMITHKLINE BEECHAM CORPORATION

  公开号：EP0677041A1

  公开（公告）日：1995-10-18
• METHODS FOR QUANTITATIVE CHIRAL DETERMINATION OF THE d- AND l- ENANTIOMERS OF AMPHETAMINE AND METHAMPHETAMINE
  申请人：Clinical Reference Laboratory, Inc.

  公开号：US20130177994A1

  公开（公告）日：2013-07-11

  Methods for the chiral separation and quantitative determination of the d- and l-enantiomers for amphetamine and methamphetamine in bodily fluids and tissues are provided. The method comprises providing a bodily fluid or tissue sample from a subject, extracting target analyte(s) from the sample, followed by eluting on a liquid chromatography column comprising a chiral stationary phase to yield an eluent, which is then analyzed for the presence of the analytes using a mass analyzer.